Skip to main content
. 2015 Nov 16;4(11):e002527. doi: 10.1161/JAHA.115.002527

Figure 5.

Figure 5

TRAIL controls FGF‐2 expression in vivo. A, Three days ischemic Trail −/− (n=4) hindlimbs express less FGF‐2 mRNA compared to WT (n=4). B, FGF‐2 mRNA expression of the gastrocnemius muscle after LacZ or TRAIL adenoviral delivery in Trail −/− (LacZ, n=5; TRAIL, n=5) and (C) WT mice (LacZ, n=6; TRAIL, n=6) after hindlimb ischemia. D, Three days VEGF‐A expression after hindlimb ischemia (WT, n=4; Trail −/−, n=4). Results are a ratio of ischemic vs control gastrocnemius muscle. FGF‐2 or VEGF‐A was normalized to 18S. Results are expressed as mean±SEM; Mann–Whitney U‐test; *P<0.05 and ***P<0.001. FGF‐2 indicates fibroblast growth factor‐2; ns, not significant; TRAIL, tumor necrosis factor–related apoptosis‐inducing ligand; VEGF, vascular endothelial growth factor; WT, wildtype.